Wuhan YZY Biopharma Co., Ltd. (YZYBIO-B) reported no changes to its registered or issued share capital for the month ended 31 August 2026, according to its latest Monthly Return filed with Hong Kong Exchanges and Clearing Limited on 3 September 2026.

Total authorised share capital remained at 193.85 million ordinary shares with a par value of RMB 1.00 each, comprising 179.48 million H shares listed in Hong Kong and 14.37 million unlisted domestic shares. The issued share count was unchanged at the same levels, and the company held no treasury shares.

Under the 2024 H Share Option Plan, 500,000 options lapsed during August, reducing the outstanding balance to 750,000. No new H shares were issued and no treasury shares were transferred as a result of option exercises. The remaining outstanding options represent approximately 0.42 % of the current H-share capital. The plan still allows for up to 18.63 million shares to be issued upon future grants and exercises, equivalent to about 10.38 % of the existing H shares.

The company confirmed compliance with Hong Kong’s minimum public-float requirement of 25 % for its listed H shares.

No warrants, convertible securities, share repurchases, or other share-related transactions were reported during the month.